External quality assessment of noninvasive fetal RHD genotyping
(2020) In Vox Sanguinis 115(5). p.466-471- Abstract
Background and objectives: Fetal RHD genotyping of cell-free maternal plasma DNA from RhD negative pregnant women can be used to guide targeted antenatal and postnatal anti-D prophylaxis for the prevention of RhD immunization. To assure the quality of clinical testing, we conducted an external quality assessment workshop with the participation of 31 laboratories. Materials and methods: Aliquots of pooled maternal plasma from gestational week 25 were sent to each laboratory. One sample was fetal RHD positive, and a second sample was fetal RHD negative. A reporting scheme was supplied for data collection, including questions regarding the methodological setup, results and clinical recommendations. The samples were tested blindly. Results:... (More)
Background and objectives: Fetal RHD genotyping of cell-free maternal plasma DNA from RhD negative pregnant women can be used to guide targeted antenatal and postnatal anti-D prophylaxis for the prevention of RhD immunization. To assure the quality of clinical testing, we conducted an external quality assessment workshop with the participation of 31 laboratories. Materials and methods: Aliquots of pooled maternal plasma from gestational week 25 were sent to each laboratory. One sample was fetal RHD positive, and a second sample was fetal RHD negative. A reporting scheme was supplied for data collection, including questions regarding the methodological setup, results and clinical recommendations. The samples were tested blindly. Results: Different methodological approaches were used; 29 laboratories used qPCR and two laboratories used ddPCR, employing a total of eight different combinations of RHD exon targets. Fetal RHD genotyping was performed with no false-negative and no false-positive results. One inconclusive result was reported for the RHD positive sample. All clinical conclusions were satisfactory. Conclusion: This external quality assessment workshop demonstrates that despite the different approaches taken to perform the clinical assays, fetal RHD genotyping is a reliable laboratory assay to guide targeted use of Rh prophylaxis in a clinical setting.
(Less)
- author
- Clausen, Frederik Banch and Hellberg, Åsa LU
- organization
- publishing date
- 2020-07
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- cell-free fetal DNA, external quality assessment, fetal RHD genotyping, Rh prophylaxis
- in
- Vox Sanguinis
- volume
- 115
- issue
- 5
- pages
- 6 pages
- publisher
- Wiley-Blackwell
- external identifiers
-
- scopus:85081750187
- pmid:32166750
- ISSN
- 0042-9007
- DOI
- 10.1111/vox.12908
- language
- English
- LU publication?
- yes
- id
- 49d56848-a6f2-4f30-b729-5d8b2d137775
- date added to LUP
- 2020-04-14 16:32:15
- date last changed
- 2024-06-12 12:53:34
@article{49d56848-a6f2-4f30-b729-5d8b2d137775,
abstract = {{<p>Background and objectives: Fetal RHD genotyping of cell-free maternal plasma DNA from RhD negative pregnant women can be used to guide targeted antenatal and postnatal anti-D prophylaxis for the prevention of RhD immunization. To assure the quality of clinical testing, we conducted an external quality assessment workshop with the participation of 31 laboratories. Materials and methods: Aliquots of pooled maternal plasma from gestational week 25 were sent to each laboratory. One sample was fetal RHD positive, and a second sample was fetal RHD negative. A reporting scheme was supplied for data collection, including questions regarding the methodological setup, results and clinical recommendations. The samples were tested blindly. Results: Different methodological approaches were used; 29 laboratories used qPCR and two laboratories used ddPCR, employing a total of eight different combinations of RHD exon targets. Fetal RHD genotyping was performed with no false-negative and no false-positive results. One inconclusive result was reported for the RHD positive sample. All clinical conclusions were satisfactory. Conclusion: This external quality assessment workshop demonstrates that despite the different approaches taken to perform the clinical assays, fetal RHD genotyping is a reliable laboratory assay to guide targeted use of Rh prophylaxis in a clinical setting.</p>}},
author = {{Clausen, Frederik Banch and Hellberg, Åsa}},
issn = {{0042-9007}},
keywords = {{cell-free fetal DNA; external quality assessment; fetal RHD genotyping; Rh prophylaxis}},
language = {{eng}},
number = {{5}},
pages = {{466--471}},
publisher = {{Wiley-Blackwell}},
series = {{Vox Sanguinis}},
title = {{External quality assessment of noninvasive fetal RHD genotyping}},
url = {{http://dx.doi.org/10.1111/vox.12908}},
doi = {{10.1111/vox.12908}},
volume = {{115}},
year = {{2020}},
}